UBC plus BSC , compared with BSC alone , did not affect the sorafenib dose reduction or interruption rate ( @ % v @ % , respectively ; P = @ ) , response rate ( @ % v @ % , respectively ; P = @ ) , or disease control rate ( @ % v @ % , respectively ; P = @ ) at week @ .